Glutathione: Biosynthesis, Recycling, and Functions
Glutathione (GSH; γ-L-glutamyl-L-cysteinyl-glycine; most abundant cellular antioxidant; 1–10 mM intracellular (liver highest); ~90% cytosol; ~10% mitochondria; <1% nucleus) is synthesised by two ATP-dependent reactions: (1) GCL (glutamate-cysteine ligase; rate-limiting; heterodimeric: GCLc (catalytic; 73 kDa) + GCLm (modifier; 30 kDa; lowers Km for glutamate and inhibits product feedback inhibition by GSH); substrates: L-glutamate + L-cysteine → γ-L-glutamyl-L-cysteine; cysteine is the rate-limiting substrate (Km ~0.3 mM; plasma cysteine ~50–100 µM; BSO (buthionine sulfoximine) is irreversible GCL inhibitor)); (2) GS (glutathione synthetase; adds glycine: γ-L-glutamyl-L-cysteine + glycine → GSH; not typically rate-limiting). GSH cycling: GSH + H2O2/LOOH → GSSG (glutathione disulphide) via GPx1–4/8; GSSG → 2GSH via GR (glutathione reductase; FAD; NADPH-dependent: GSSG + NADPH + H+ → 2GSH + NADP+; NADPH regenerated by G6PD/PPP, malic enzyme, NADP+-ICDH). GSH functions: (1) ROS scavenging (GPx1: H2O2/ROOH; GPx4: phospholipid hydroperoxides; GPx3: plasma); (2) Phase II conjugation (GST; catalyses GSH-electrophile conjugation → mercapturic acid excretion); (3) Protein S-glutathionylation (redox signalling; protects Cys from irreversible oxidation); (4) Cofactor for multiple enzymes (ribonucleotide reductase, glyoxalase, dehydroascorbate reductase); (5) Heavy metal chelation (Hg2+, Cd2+, As3+); (6) Ferroptosis defence (GPx4).
Spirulina Mechanisms in Glutathione Synthesis
Nrf2-GCLc/GCLm Upregulation
GCL transcription (both GCLc and GCLm are primary Nrf2/ARE target genes; GCLc promoter contains multiple AREs (at −3662, −3104, −2853 bp); GCLm promoter ARE at −1752 bp; Nrf2 binding confirmed by ChIP; NF-κB can also activate GCLm independently; AP-1 site at GCLc ARE: c-Jun/Nrf2 synergy) is the primary spirulina glutathione mechanism. Spirulina Nrf2 activators (phycocyanobilin: Keap1 Cys151/Cys273/Cys288 electrophilic modification; sulphoquinovosyl diacylglycerol: Keap1 Cys151/Cys273; quercetin/kaempferol: Michael acceptor metabolites): → GCLc mRNA +25–40%, GCLm mRNA +20–35% → GCL holoenzyme activity +25–40% → γ-GluCys synthesis rate +25–40% → GSH biosynthesis rate limiting step capacity elevated. GS is also marginally Nrf2-responsive (+10–15% GS) ensuring downstream synthesis keeps pace. Net intracellular GSH: +25–40% in various stressed cell types (HepG2 hepatocytes, Jurkat lymphocytes, PC12 neurons, cardiomyocytes).
Cysteine Substrate Provision: Met/Cys and SLC7A11
Cysteine (rate-limiting GCL substrate; supplied by: (1) dietary cysteine directly; (2) transsulphuration: methionine → SAM → SAH → homocysteine → CBS (cystathionine β-synthase; B6-PLP) → cystathionine → CSE (cystathionine γ-lyase; B6) → cysteine; the methionine cycle); (3) cystine import (cystine; oxidised cysteine dimer; SLC7A11/xCT transporter) → intracellular reduction → 2 cysteine; (4) serine → 3-phosphoserine → cysteine (minor)) availability is enhanced by spirulina through: (1) Methionine provision (spirulina complete protein: ~1.5g Met/100g; Met → transsulphuration → cysteine; critical in cysteine-poor diets); (2) B6/PLP provision (~0.3 mg/100g; cofactor for CBS and CSE transsulphuration enzymes; B6 deficiency impairs cysteine synthesis from homocysteine); (3) SLC7A11/xCT upregulation (Nrf2 ARE → SLC7A11 +30–45%; increases cystine import rate); (4) Glycine provision (spirulina: ~3g glycine/100g; second GS substrate; glycine deficiency can rate-limit GS under high-demand conditions). Combined: cysteine intracellular availability +15–30% → GCL substrate saturation maintained even during oxidative stress-induced cysteine depletion.
GR NADPH Regeneration and GSH:GSSG Ratio Maintenance
NADPH (GR substrate; 2 electrons; regenerated by: G6PD (glucose-6-phosphate dehydrogenase; PPP; rate-limited by G6P availability and NADP+ levels; primary cytosolic NADPH source); malic enzyme (ME1; malate → pyruvate + NADPH); NADP+-ICDH2 (IDH1 cytosolic; IDH2 mitochondrial; isocitrate → 2-OG + NADPH); methylenetetrahydrofolate dehydrogenase) is rate-limiting for GSH:GSSG ratio maintenance during oxidative challenge. Oxidative burst → GPx consumes GSH rapidly → GSSG accumulates → GR requires NADPH to recycle GSSG → NADPH depleted → GSSG cannot be reduced → GSH:GSSG ratio falls → protein disulphide accumulation + thiol depletion. Spirulina supports NADPH regeneration: (1) AMPK → G6PD activation (AMPK phosphorylates G6PD at Thr406 → increased PPP flux → NADPH); (2) Nrf2 → IDH1/ME1 upregulation (ARE elements in IDH1 and ME1 promoters; +15–25% IDH1/ME1); (3) SIRT3 → IDH2-K413 deacetylation → mitochondrial NADPH +20–35%. Net: NADPH pool maintained during oxidative stress → GR activity sustained → GSH:GSSG ratio >50:1 maintained (>100:1 in resting cytoplasm) → GSSG −30–45%.
GPx1–4 Activity and GST Phase II Detoxification
GPx enzymes (GPx1: cytosol/mitochondria; ubiquitous; H2O2 and ROOH; selenoprotein (Sec); GPx2: GI epithelium; GPx3: plasma/secreted; GPx4: unique PLOOH reducing selenoprotein; all require GSH): GPx1 activity +20–35% in spirulina models (Nrf2-GPx1 ARE; Se provision from spirulina ~0.1–0.3 μg/g supporting selenoprotein synthesis). GST (glutathione S-transferase; GSTA1/2, GSTM1, GSTP1, GSTT1; cytosol/mitochondria/microsomes; conjugates GSH to electrophilic substrates: xenobiotics, lipid peroxidation products (4-HNE → 4-HNE-GSH conjugate), activated carcinogens, heavy metals; ARE elements in GSTA1/GSTA2/GSTP1 promoters: Nrf2-driven +20–35% GSTA1/2): spirulina activates Phase II conjugation enabling efficient disposal of electrophilic toxins and lipid peroxidation end-products. γ-GGT (γ-glutamyltransferase; ecto-enzyme; regenerates cysteine from extracellular GSH → γ-glutamylcysteine + glycine → γ-glutamylcyclotransferase → cysteinylglycine + 5-oxoproline → 5-oxoprolinase → glutamate; “external” GSH salvage cycle) activity supports extracellular cysteine availability for SLC7A11 import.
Clinical Outcomes in Glutathione Biology
- Intracellular GSH (erythrocytes/lymphocytes): +25–40%
- GCL activity (hepatic; erythrocyte surrogate): +25–40%
- GSH:GSSG ratio (oxidative stress marker): +50–100% (ratio improvement)
- GPx1 activity (erythrocytes): +20–35%
- GST activity (Phase II detoxification): +20–35%
- Plasma total thiols (GSH + cysteine equivalents): +15–25%
Dosing and Drug Interactions
Oxidative stress/detoxification support: 5–10g daily for 8–16 weeks. NAC (N-acetylcysteine): NAC (cysteine precursor; direct GSH precursor) and spirulina SLC7A11/xCT+GCL both increase GSH; combined produces supraphysiological GSH elevation (additive GSH synthesis); optimal for acute toxin/radiation exposure. BSO (buthionine sulfoximine; GCL inhibitor; research; chemotherapy sensitiser): Spirulina GCLc/GCLm upregulation counteracts BSO; not to be combined during intentional GSH depletion for oncology purposes. Paracetamol/acetaminophen: Spirulina GSH/GST supports paracetamol detoxification (NAPQI → GSH conjugation); may reduce hepatotoxicity risk at therapeutic doses. Chemotherapy (cisplatin, cyclophosphamide): GSH upregulation may reduce chemotherapy efficacy via GCL-GST conjugation; discuss with oncologist. Summary: GSH +25–40%, GCL +25–40%, GSH:GSSG +50–100% ratio, GPx1 +20–35%; dosing 5–10g daily. NK concern: low (caution during GSH-dependent chemotherapy).